Medexus Pharmaceuticals（MDP）株式概要
メデクサス・ファーマシューティカルズ・インクはカナダと米国で製薬会社として活動している。 詳細
MDP Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medexus Pharmaceuticals Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | CA$4.20 |
| 52週高値 | CA$4.29 |
| 52週安値 | CA$2.47 |
| ベータ | 1.84 |
| 1ヶ月の変化 | 8.25% |
| 3ヶ月変化 | 38.16% |
| 1年変化 | 33.33% |
| 3年間の変化 | 125.81% |
| 5年間の変化 | -43.32% |
| IPOからの変化 | -44.00% |
最新ニュース
ナラティブの更新 • Jun 17
MDP: Share Repurchases And New Cell Therapy Rights Will Support Upside
Analysts have modestly adjusted their fair value price target for Medexus Pharmaceuticals stock to CA$8.00, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations, while keeping the overall valuation level unchanged. What's in the News for Medexus Pharmaceuticals Secured exclusive Canadian rights to commercialize UM171 Cell Therapy, branded as Zemcelpro (dorocubicel) in Europe, through a license and supply agreement with ExCellThera and its subsidiary Cordex Biologics.ナラティブの更新 • Jun 02
MDP: Ongoing Share Repurchases Will Support Upside Potential
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E as the key drivers of the revised valuation. What's in the News Medexus reported an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, with 56 healthcare institutions having granted positive formulary inclusion decisions as of March 31, 2026, and 64 transplant centers having ordered the product for procedures.ナラティブの更新 • Apr 27
MDP: Share Repurchases And Transplant Center Adoption Will Support Upside
Analysts have modestly raised their CA$ price target on Medexus Pharmaceuticals, citing slightly higher modeled revenue growth of 21.21% and a profit margin assumption of 24.84%, while keeping the fair value and discount rate unchanged. What's in the News Medexus provided an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, including recent progress with transplant center formulary decisions and ordering activity.Recent updates
ナラティブの更新 • Jun 17
MDP: Share Repurchases And New Cell Therapy Rights Will Support Upside
Analysts have modestly adjusted their fair value price target for Medexus Pharmaceuticals stock to CA$8.00, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations, while keeping the overall valuation level unchanged. What's in the News for Medexus Pharmaceuticals Secured exclusive Canadian rights to commercialize UM171 Cell Therapy, branded as Zemcelpro (dorocubicel) in Europe, through a license and supply agreement with ExCellThera and its subsidiary Cordex Biologics.ナラティブの更新 • Jun 02
MDP: Ongoing Share Repurchases Will Support Upside Potential
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E as the key drivers of the revised valuation. What's in the News Medexus reported an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, with 56 healthcare institutions having granted positive formulary inclusion decisions as of March 31, 2026, and 64 transplant centers having ordered the product for procedures.ナラティブの更新 • Apr 27
MDP: Share Repurchases And Transplant Center Adoption Will Support Upside
Analysts have modestly raised their CA$ price target on Medexus Pharmaceuticals, citing slightly higher modeled revenue growth of 21.21% and a profit margin assumption of 24.84%, while keeping the fair value and discount rate unchanged. What's in the News Medexus provided an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, including recent progress with transplant center formulary decisions and ordering activity.ナラティブの更新 • Apr 09
MDP: Share Buyback And Higher Future P E Multiple Will Support Upside
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth, profit margins, and future P/E that refine their outlook on the company’s valuation. What's in the News Medexus Pharmaceuticals completed a share buyback tranche covering 191,900 shares, equal to 0.59% of its shares, between November 20, 2025 and December 31, 2025 (Key Developments).ナラティブの更新 • Mar 26
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have modestly lifted their price target on Medexus Pharmaceuticals to CA$8.00, reflecting slightly higher modeled revenue growth, a small uptick in profit margin assumptions, and a marginally lower future P/E multiple. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares from November 20, 2025 to December 31, 2025, representing 0.59% of its shares, for a total of CA$0.52 million under its previously announced buyback program (Key Developments).ナラティブの更新 • Mar 11
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have raised their CA$ price target on Medexus Pharmaceuticals, citing slightly stronger modeled revenue growth of 19.57% and a profit margin of 27.71%, along with a modestly lower forward P/E of 4.80x in their updated assumptions. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of shares, for CAD 0.52 million under its buyback program announced on November 20, 2025 (Key Developments).ナラティブの更新 • Feb 25
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have revised their CA$ price target on Medexus Pharmaceuticals upward, reflecting updated assumptions that include modeled revenue growth of 19.35%, a profit margin of 27.36% and a slightly lower forward P/E of 4.85x. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of its outstanding equity, for a total cost of CA$0.52 million under the buyback announced on November 20, 2025 (Key Developments).ナラティブの更新 • Feb 10
MDP: Share Repurchase Plan Will Support Higher Future Shareholder Value
Analysts have modestly adjusted their price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth of about 17.94%, profit margin of about 25.99% and a future P/E of about 5.10x. Together, these figures inform a refreshed fair value view of US$8.00 per share.ナラティブの更新 • Jan 26
MDP: Share Repurchase Plan Will Support Stronger Future Shareholder Returns
Analysts have lifted their price target on Medexus Pharmaceuticals to US$8.00 from US$8.00, citing slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a small adjustment to the future P/E assumption. What's in the News Medexus Pharmaceuticals has announced a share repurchase program that allows the company to buy back up to 2,983,650 shares, or 9.2% of its issued share capital, with all repurchased shares set to be cancelled.ナラティブの更新 • Jan 11
MDP: Share Repurchase Program Will Support Stronger Future Shareholder Returns
Analysts have reaffirmed their price target on Medexus Pharmaceuticals at US$8.00, citing updated assumptions for revenue growth, profit margins, and future P/E that adjust their overall outlook while keeping the fair value level unchanged. What's in the News Medexus Pharmaceuticals Inc.分析記事 • Jan 03
Does Medexus Pharmaceuticals (TSE:MDP) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブの更新 • Dec 16
MDP: Share Repurchase Program Will Drive Stronger Future Shareholder Returns
Analysts have raised their price target for Medexus Pharmaceuticals to approximately $8.00 per share from about $6.00, citing expectations of stronger revenue growth, a substantial improvement in profit margins, and a lower projected future P/E multiple that enhances the stock's valuation appeal. What's in the News Medexus Pharmaceuticals Inc.
ナラティブの更新 • Aug 20
US Transplant Centers Will Drive Specialty Care Adoption
Despite notable improvements in net profit margin and revenue growth forecasts, the consensus analyst price target for Medexus Pharmaceuticals has been revised downward from CA$7.11 to CA$6.71. What's in the News Medexus Pharmaceuticals received approval from US CMS for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX™ (treosulfan) for Injection for fiscal year 2026.ナラティブの更新 • Aug 06
US Transplant Centers Will Drive Specialty Care Adoption
The notable increase in Medexus Pharmaceuticals' consensus price target is primarily driven by a significant rise in its future P/E valuation, with fair value revised upward from CA$6.50 to CA$7.11. Valuation Changes Summary of Valuation Changes for Medexus Pharmaceuticals The Consensus Analyst Price Target has risen from CA$6.50 to CA$7.11.分析記事 • May 04
Earnings Tell The Story For Medexus Pharmaceuticals Inc. (TSE:MDP) As Its Stock Soars 28%
Those holding Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares would be relieved that the share price has rebounded 28...
新しいナラティブ • Feb 19
FDA Approval Of GRAFAPEX Will Unlock Market Potential With 7 Years Exclusivity
Successful FDA approval for GRAFAPEX is expected to significantly increase revenue, providing a robust new stream with its granted exclusivity.分析記事 • Jan 19
Investors Appear Satisfied With Medexus Pharmaceuticals Inc.'s (TSE:MDP) Prospects As Shares Rocket 52%
Despite an already strong run, Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have been powering on, with a gain of...分析記事 • Dec 05
After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 31% after a shaky period...分析記事 • Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Medexus Pharmaceuticals Inc.'s ( TSE:MDP ) stock was strong despite it releasing a soft earnings report last week. We...分析記事 • Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Medexus Pharmaceuticals Inc. ( TSE:MDP ) just released its latest quarterly results and things are looking bullish. It...分析記事 • Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shareholders have had their patience rewarded with a 29% share price jump in...分析記事 • Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...分析記事 • Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
The Medexus Pharmaceuticals Inc. ( TSE:MDP ) share price has softened a substantial 26% over the previous 30 days...分析記事 • Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 89% after a shaky period...分析記事 • Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...株主還元
| MDP | CA Pharmaceuticals | CA 市場 | |
|---|---|---|---|
| 7D | 0% | -0.09% | -0.4% |
| 1Y | 33.3% | 54.4% | 30.3% |
業界別リターン: MDP過去 1 年間で54.4 % の収益を上げたCanadian Pharmaceuticals業界を下回りました。
リターン対市場: MDP過去 1 年間で30.3 % の収益を上げたCanadian市場を上回りました。
価格変動
| MDP volatility | |
|---|---|
| MDP Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in CA Market | 16.5% |
| 10% least volatile stocks in CA Market | 3.7% |
安定した株価: MDP 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: MDPの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2000 | 91 | Ken d'Entremont | www.medexus.com |
メデクサス・ファーマシューティカルズ社はカナダと米国で製薬会社として活動している。同社は腫瘍学、血液学、リウマチ学、自己免疫疾患、アレルギー学、皮膚科学などの治療分野に注力している。主な製品は、血友病B患者用の遺伝子組換え型血液凝固第IX因子製剤であるIXINITY、関節リウマチおよびその他の自己免疫疾患治療用のメトトレキサート製剤であるRasuvoおよびMetoject、処方用アレルギー薬であるRupall、手術中の悪性組織の可視化の補助として神経膠腫患者に適応のある光イメージング剤であるGleolanである。同社の製品ポートフォリオには、グリコピロレート内用液のCuvposa、Pediapharm社のナプロキセン懸濁液のNaproxen、シプロフロキサシンとフルシノロンアセトニドのOtixal、トリアムシノロンヘキサセトニド注射用懸濁液のTrispan、同種造血幹細胞移植を受ける患者のコンディショニング治療の一部として使用される二官能性アルキル化剤のTrecondyvも含まれる。また、市販薬として、アタマジラミ駆除を適応とする局所画期的治療薬Nyda、成人の臨時便秘を治療する浸透圧性下剤Relaxa、変形性膝関節症の関節痛を軽減し関節機能を強化するOralvisc、Calcia CalciumおよびビタミンD製品を提供している。同社は以前Pediapharm Inc.として知られていたが、2018年12月にMedexus Pharmaceuticals Inc.に社名を変更した。メデクサス・ファーマシューティカルズ・インクはカナダのトロントに本社を置いている。
Medexus Pharmaceuticals Inc. 基礎のまとめ
| MDP 基礎統計学 | |
|---|---|
| 時価総額 | CA$133.71m |
| 収益（TTM） | -CA$3.39m |
| 売上高(TTM) | CA$140.86m |
0.9x
P/Sレシオ-39.4x
PER（株価収益率MDP は割高か？
公正価値と評価分析を参照収益と収入
| MDP 損益計算書（TTM） | |
|---|---|
| 収益 | US$99.33m |
| 売上原価 | US$35.48m |
| 売上総利益 | US$63.86m |
| その他の費用 | US$66.25m |
| 収益 | -US$2.39m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.075 |
| グロス・マージン | 64.29% |
| 純利益率 | -2.41% |
| 有利子負債／自己資本比率 | 45.4% |
MDP の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/28 08:41 |
| 終値 | 2026/06/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Medexus Pharmaceuticals Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Scott Henry | Alliance Global Partners |
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |